Farmitalia Carlo Erba S.p.a.

Carlo Erba S.p.a.

Farmitalia Carlo Erba

Farmitalia Certo Erba S.p.a.

Roberto Ceserani

Carmelo Gandolfi

Franco Faustini

Carlo Passarotti

Maria M Usardi

Angelo Fumagalli

Alessandro Andreoni

Renato Pellegata

Achille Panzeri

Enrico Di Salle

Fabrizio Orzi

Roberto De Castiglione

Ugo Scarponi

Anna M Lazzarini

Daniela Toti

Franco Fanstini

Allesandro Andreoni

Renato Castello

Fabrizio Vaghi

Walter Moretti

Mario M Usardi

William Fava

A compound of formula I: ##STR1## wherein either (i) each of R.sub.1 and R.sub.2 independently represents a hydrogen atom or an organic group, or (ii) R.sub.1 and R.sub.2 linked together form a heterocyclic ring or (iii) R.sub.2 is hydrogen and R.sub.1 is ##STR2## wherein each of R.sub.6 and R.sub.7 independently represents hydrogen or an organic group, n is 0-3, X is O, S, NH, NR.sub.8, CHNO.sub.2 or CHSO.sub.2 R.sub.4, wherein R.sub.8 and R.sub.4 are organic groups and R.sub.3 represents an organic group. The compound of formula I is effective as an anti-ulcer agent and is highly effective as a histamine H.sub.2 -receptor antagonist.

Ulcer and gastric secretion inhibiting

The present invention relates to new furyl derivatives of 16-substituted prostaglandins, to a process for their preparation and to pharmaceutical and veterinary compositions containing them. The new compounds of the invention are optically active or racemic prostaglandins of the following formula (I) ##STR1## wherein R is

Furyl derivatives of 16-substituted prostaglandins

Omega furyl prostenynoic acids have been prepared.

13,14-Didehydro-prostaglandins and process for their preparation

.omega.-Nor-cycloalkyl-13,14-dehydro-prostaglandin compounds, specifically 5c-9-oxo-11.alpha.,15S-dihydroxy-20,19,18-tirnor-17-cyclohexyl-prost-5-en- 13-ynoic acid, the esters and salts thereof, having antiulcer and luteolytic activity, are disclosed.

.omega.-Nor-cycloalkyl-13,14-dehydro-prostaglandins and process for

2-oxa-bicyclic prostaglandins are provided, together with methods for their preparation and pharmaceutical and veterinary compositions containing same. The compounds have a wide range of pharmacological utilities, such as hypotensive agents, vasodilatory agents, and anti-aggregating agents.

Certain PGI.sub.1 compounds and their pharmaceutical composition and

15-Epi-Prostacyclin derivatives and compositions containing them having numerous pharmaceutical and veterinary utilities including, for example, anti-aggregating activity and anti-thrombolytic activity. Methods for preparing and using the compounds are also disclosed.

15-Epi-prostacyclin and analogous prostacyclins

9-deoxy-9A-methylene-isosteres of PGI.sub.2, including processes for their preparation and pharmaceutical and veterinary compositions containing same, are disclosed. The compounds are useful as therapeutic agents, for example as anti-aggregating agents, disaggregating agents, and as vasodilators.

9-Deoxy-9A-methylene isosteres of PGI.sub.2 and process for their

Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities, including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Bicyclic prostaglandins and process for their preparation

Bicyclic prostaglandins and pharamaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities, including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Pharmaceutically useful 5,6-saturated PGI compounds

Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds are also disclosed.

Bicyclic prostaglandins

Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities including, for example, hypotensive, vasodilatory, antiaggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Bicyclic Prostaglandins and pharmaceutical and veterinary compositions containing them, having numerous pharmaceutical and veterinary utilities, including for example hypotensive, vasodilatory, anti-aggregating, and anti-thrombotic activities. Methods for preparing the compounds and compositions are also disclosed.

Bicyclic prostaglandins having numerous pharmaceutical and veterinary utilities including, for example, use as hypotensive, vasodilatory, anti-aggregating, cytoprotective, and bronchodilatory agents. Pharmaceutical and veterinary compositions comprising the compounds in combination with pharmaceutically and/or veterinarily acceptable carriers and/or diluents are also disclosed.

Certain 13,14-didehydro-PGI.sub.1 compounds

Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them, having numerous pharmaceutical and veterinary utilities, including for example hypotensive, vasodilatory, anti-aggregating, and anti-thrombotic activities. Methods for preparing the compounds and compositions are also disclosed.

Growing community of inventors

Milan, Italy

Roberto Ceserani